Your browser doesn't support javascript.
loading
The glucagon receptor antagonist LY2409021 does not affect gastrointestinal-mediated glucose disposal or the incretin effect in individuals with and without type 2 diabetes.
Hædersdal, Sofie; Lund, Asger; Nielsen-Hannerup, Elisabeth; Maagensen, Henrik; Forman, Julie L; Holst, Jens J; Knop, Filip K; Vilsbøll, Tina.
Afiliação
  • Hædersdal S; Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Lund A; Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
  • Nielsen-Hannerup E; Danish Diabetes Academy, Odense University Hospital, Odense, Denmark.
  • Maagensen H; Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Forman JL; Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
  • Holst JJ; Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Knop FK; Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
  • Vilsbøll T; Clinical Research, Copenhagen University Hospital - Steno Diabetes Center Copenhagen, Herlev, Denmark.
Eur J Endocrinol ; 187(4): 507-518, 2022 Oct 01.
Article em En | MEDLINE | ID: mdl-35977072
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Incretinas Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Incretinas Idioma: En Ano de publicação: 2022 Tipo de documento: Article